Literature DB >> 7829606

The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome.

P J Jenkins1, P J Trainer, P N Plowman, W S Shand, A B Grossman, J A Wass, G M Besser.   

Abstract

We have reviewed our experience of adrenalectomy performed as part of the management of 56 patients with ACTH-dependent Cushing's syndrome between 1946 and 1993. Forty-three patients were operated on at our institution. Surgery-related mortality did not occur, but complications developed in 14 (33%); these were minor in 12. Eleven patients (29%) of the 38 for whom long-term follow-up data were available and who did not have a proven ectopic source of ACTH subsequently developed Nelson's syndrome, diagnosed on the basis of clinical pigmentation and markedly elevated ACTH levels that were not normally suppressible with glucocorticoids. The effects of prophylactic pituitary radiotherapy were assessed in 38 patients who underwent adrenalectomy at our institution and 18 who underwent surgery elsewhere. Patients who had received prophylactic radiotherapy were less likely to develop Nelson's syndrome (5 of 20, 25%) compared to those who did not (18 of 36, 50%; P > 0.07), and there was a low incidence of radiotherapy-induced hypopituitarism. We conclude that total adrenalectomy has proved to be a safe and effective operation and still may be indicated in selected patients with ACTH-dependent Cushing's syndrome; because prophylactic pituitary radiotherapy reduces the incidence of subsequent Nelson's syndrome by 50%, it should always be considered in the management of these patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829606     DOI: 10.1210/jcem.80.1.7829606

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Bilateral adrenalectomy for Cushing's disease.

Authors:  Laurence Katznelson
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Nelson's syndrome post-bilateral adrenalectomy.

Authors:  P Iglesias; V Rodríguez-Berrocal; H Pian; J J Díez
Journal:  QJM       Date:  2016-06-11

4.  Early diagnosis of Nelson's syndrome.

Authors:  A A Kasperlik-Zaluska; J Walecki; W Jeske; B Migdalska; J Janik; W Bonicki; J Brzeziński; A Makowska; A Brzezińska
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 5.  Progression of a Nelson's adenoma to pituitary carcinoma; a case report and review of the literature.

Authors:  S A Kemink; P Wesseling; G F Pieters; A A Verhofstad; A R Hermus; A G Smals
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

6.  Laparoscopic unilateral and bilateral adrenalectomy for Cushing's syndrome. Transperitoneal and retroperitoneal approaches.

Authors:  L Fernández-Cruz; A Saenz; G Benarroch; E Astudillo; P Taura; L Sabater
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

Review 7.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

8.  Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

Authors:  Marie S Thearle; Pamela U Freda; Jeffrey N Bruce; Steven R Isaacson; Yoomi Lee; Robert L Fine
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

9.  An unusual presentation of Nelson's syndrome with apoplexy and subarachnoid hemorrhage.

Authors:  Nurperi Gazioğlu; Pinar Kadioğlu; Eylem Ocal; Haldun Erman; Ziya Akar; Büge Oz
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 10.  An approach to the management of patients with residual Cushing's disease.

Authors:  Lewis S Blevins; Nader Sanai; Sandeep Kunwar; Jessica K Devin
Journal:  J Neurooncol       Date:  2009-04-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.